Lars Vedin - Abliva AB Consultant

All Insiders . Sweden . 
Stock . Abliva AB . Stakeholders . Insider . Lars Vedin
ABLI Stock  SEK 0.43  0.01  2.38%   

Insider

Lars Vedin is Consultant of Abliva AB
Phone46 4 62 75 62 20
Webhttps://abliva.com

Abliva AB Management Efficiency

The company has return on total asset (ROA) of (0.4101) % which means that it has lost $0.4101 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.805) %, meaning that it generated substantial loss on money invested by shareholders. Abliva AB's management efficiency ratios could be used to measure how well Abliva AB manages its routine affairs as well as how well it operates its assets and liabilities.
Abliva AB has accumulated 92 K in total debt. Abliva AB has a current ratio of 2.7, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Abliva AB until it has trouble settling it off, either with new capital or with free cash flow. So, Abliva AB's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Abliva AB sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Abliva to invest in growth at high rates of return. When we think about Abliva AB's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Dominique TersagoCantargia AB
61
Susanne LagerlundCantargia AB
N/A
Annika MBAOncopeptides AB
57
MSc MDOncopeptides AB
N/A
Malin CarlssonAlligator Bioscience AB
55
Jeroen MDMendus AB
52
Ignacio GarciaRibasCantargia AB
N/A
Johanna ChristensenCantargia AB
N/A
Julie SilberAlligator Bioscience AB
N/A
PerOlof GunnessonMendus AB
78
Sumeet MDAlligator Bioscience AB
N/A
Erik MantingMendus AB
52
Sren BregenholtAlligator Bioscience AB
52
MarcussCantargia AB
N/A
Linda HolmstromOncopeptides AB
N/A
Thoas MDCantargia AB
61
Kjell SjstrmCantargia AB
N/A
Leopold BerteaMendus AB
58
Adnan DeronicCantargia AB
N/A
Lotta FermMendus AB
57
Pr MDOncopeptides AB
N/A
Abliva AB , a pharmaceutical company, engages in the research and development of mitochondrial medicine. Abliva AB was incorporated in 2000 and is headquartered in Lund, Sweden. Abliva AB is traded on Stockholm Stock Exchange in Sweden. Abliva AB (ABLI) is traded on Stockholm Exchange in Sweden and employs 8 people.

Management Performance

Return On Equity-0.8
Return On Asset-0.41

Abliva AB Leadership Team

Elected by the shareholders, the Abliva AB's board of directors comprises two types of representatives: Abliva AB inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Abliva. The board's role is to monitor Abliva AB's management team and ensure that shareholders' interests are well served. Abliva AB's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Abliva AB's outside directors are responsible for providing unbiased perspectives on the board's policies.
Lars Vedin, Consultant
Magnus Hansson, Chief Devel
Eskil Elmr, Chief Discovery
Ellen Donnelly, Chief Officer
Catharina Johansson, CFO CEO
Daniel Schale, Director Communications

Abliva Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Abliva AB a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity-0.8
Return On Asset-0.41
Current Valuation103.38 M
Shares Outstanding1.06 B
Shares Owned By Insiders7.79 %
Shares Owned By Institutions49.04 %
Price To Book0.97 X
Price To Sales2,681 X
Revenue151 K
Gross Profit(103.54 M)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Abliva Stock Analysis

When running Abliva AB's price analysis, check to measure Abliva AB's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Abliva AB is operating at the current time. Most of Abliva AB's value examination focuses on studying past and present price action to predict the probability of Abliva AB's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Abliva AB's price. Additionally, you may evaluate how the addition of Abliva AB to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY